Brief: Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib
14/04/2025 11:08
April 14 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES SUCCESSFUL FDA TYPE D MEETING ON PHASE 3 REGISTRATIONAL TRIAL DESIGN FOR DAROVASERTIB AS NEOADJUVANT THERAPY FOR PRIMARY UVEAL MELANOMA IDEAYA BIOSCIENCES-TARGETING TO INITIATE PHASE 3 RANDOMIZED REGISTRATIONAL TRIAL FOR DAROVASERTIB IN NEOADJUVANT SETTING IN PRIMARY UM IN H1 2025 Source text: ID:nPn51pd8ba Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj